In this exclusive PC Podcast interview, Brandon Newman, Xevant’s CEO and founder, explores:
- The implications of the Inflation Reduction Act’s price negotiation provisions, and how these could result in ripple effects across the healthcare system
- The role that pharmacy benefit managers (PBMs) and other intermediaries’ play when it comes to determining drug costs, and how spread pricing is involved
- How Xevant helps improve drug cost transparency efforts
- Strategies for affordability Newman would offer the pharma industry that can be implemented immediately
The latest episode of The Pharmaceutical Commerce Podcast is available directly on SoundCloud.
